Skip to main content

Table 2 Summary of reports in literature (continued)

From: Breast carcinoma with choriocarcinomatous features: a case report and review of the literature

Patients

ER

PR

Ki-67

EMA

PLAP

P53

Follow-up

Metastasis

Treatment

References

1

+

+

DFS

Lung, kidney

S + C

Present study

2

/

+

+

/

Died

Lung, chest wall, liver

S + C + R + E

[7]

3

+

/

/

/

/

/

No

S

[9]

4

/

/

/

/

/

/

Died

Left parietal lobe

C + R

[10]

5

+

+

/

/

DFS

No

S

[11]

6

/

100

/

/

DFS

No

S + C

[8]

7

/

/

/

/

Died

Back neck, Pelvis, lungs

S + C

[8]

8

+

17

/

Lost

/

S + C + R

[3]

9

+

40

/

+

DFS

No

S + C + R

[3]

10

+

10

/

+

DFS

No

S + C + R

[3]

11

2

/

Lost

/

S

[3]

12

/

/

/

/

/

/

Died

Lung, Lymph nodes

S

[4]

13

/

/

/

/

/

/

DFS

Lymph nodes

S + E

[12]

14

/

/

/

/

/

/

/

Lungs, skin

C

[13]

15

+80%

/

/

DFS

No

S

[14]

16

+80%

/

/

+

DFS

No

S

[14]

17

/

/

/

/

/

/

S + C

[15]

18

/

/

/

/

/

/

Died

Lung, Liver, Kidneys

C

[5]

  1. “+”, Positive; “–”, Negative; “/”, Unknown. “Lost”, Lost to follow-up.
  2. L, Left breast; R, Right breast; LN, Lymph node status; IDC-DCIS, Infiltrating ductal carcinoma-ductal carcinoma in situ; HPL, Human placental lactogen; HCG, Human chorionic gonadotropin; CK, Cytokeratin; ER, Estrogen receptor; PR, Progesterone receptor; EMA, Epithelial membrane antigen; PALP, Placental alkaline phosphatase; DFS, Disease free survival; S, Surgery; C, Chemotherapy; R, Radiotherapy; E, Endocrine therapy.